Live News REGULATION L impact Jul 06, 2026, 01:10 AM UTC

Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor

Ascletis Submits Two IND Applications to the U.S. FDA f

ASC35 ASC36 ASC3635 FDA FDC GIPR GLP-1R IND U.S

SQUAWKNEWS Updated Jul 06, 2026, 01:11 AM UTC

Ascletis Submits Two IND Applications to the U.S.

FDA f